查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585840

支气管扩张剂市场：按药物类别、给药途径、疾病和最终用户划分 - 全球预测 2025-2030

Bronchodilators Market by Drug Class (Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, Xanthine Derivative), Route of Administration (Injectable, Nasal, Oral), Disease, End-users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

根据预测，2023年支气管扩张剂市值为183.7亿美元，预计2024年将达到192亿美元，复合年增长率为5.98%，到2030年将达到275.9亿美元。

市场区隔市场区隔是更广泛的呼吸治疗市场的一个重要部分，主要用于放鬆和拓宽肺部的气道，改善气流以及治疗气喘和慢性阻塞性肺病（用于放鬆的慢性阻塞性肺病）等疾病。支气管扩张剂的需求是由于全球呼吸系统疾病的盛行率不断上升，特别是环境污染、吸烟和工业事故发生率的上升。支气管扩张剂的应用涵盖多种给药方式，包括吸入器、雾化器和口服药物，以满足急性和慢性治疗需求。这些药物有多种最终用途，从医院的紧急治疗到需要长期控制病情的患者的日常家庭使用。市场成长受到药物输送系统技术进步、意识增强以及针对个别患者情况客製化个人化医疗的需求的强烈影响。此外，发展中地区医疗基础设施的兴起带来了潜在的扩张机会。关键的成长机会在于研究和开发新配方以减少副作用并提高效率，以及使用数位健康平台更好地监测和管理呼吸系统疾病。然而，市场并非没有挑战，严格的监管要求、高昂的开发成本以及长期使用相关的潜在副作用是主要障碍。生物疗法等竞争治疗方法也威胁市场占有率。创新途径是存在的，包括探索新型化合物、改善患者依从性技术以及整合人工智慧以提供预测性医疗服务。支气管扩张剂市场的性质是高度动态的，大量持续的併购活动旨在加强产品平臺和策略性区域扩张，并不断适应监管条件和消费者需求。

主要市场统计
基准年[2023] 183.7亿美元
预测年份 [2024] 192亿美元
预测年份 [2030] 275.9亿美元
复合年增长率（%） 5.98%

市场动态：揭示快速发展的支气管扩张剂市场的关键市场洞察

支气管扩张剂市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球呼吸系统疾病盛行率上升
    • 提高对气喘和囊肿纤维化等呼吸系统疾病的认识
  • 市场限制因素
    • 治疗慢性支气管炎需要巨额费用
  • 市场机会
    • 积极开发新药研究活动 支气管扩张剂
    • 慢性支气管炎治疗的临床试验增加
  • 市场挑战
    • 与服用支气管扩张剂相关的副作用

波特的五力：驾驭支气管扩张剂市场的策略工具

波特的五力架构是了解支气管扩张剂市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解支气管扩张剂市场的外部影响

外部宏观环境因素在塑造支气管扩张剂市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解支气管扩张剂市场的竞争格局

支气管扩张剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵支气管扩张剂市场供应商的绩效评估

FPNV定位矩阵是评估支气管扩张剂市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，绘製支气管扩张剂市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，支气管扩张剂市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地呼吸系统疾病的发生率正在上升
      • 提高对气喘和囊肿纤维化等呼吸系统疾病的认识
    • 抑制因素
      • 治疗慢性支气管炎需要庞大资金
    • 机会
      • 旨在新开发的强有力的研究活动
      • 治疗慢性支气管炎的临床试验增加
    • 任务
      • 与服用支气管扩张剂相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的支气管扩张剂市场

  • 抗胆碱能支气管扩张剂
  • β-肾上腺素能支气管扩张剂
  • 黄嘌呤衍生物

第七章支气管扩张剂市场：依给药途径

  • 可注射的
  • 鼻腔
  • 口服

第八章支气管扩张剂市场：依疾病分类

  • 气喘
  • 慢性阻塞性肺病

第九章支气管扩张剂市场：依最终用户分类

  • 医院
  • 专科诊所

第10章美洲支气管扩张剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区支气管扩张剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲支气管扩张剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AdvaCare Pharma
  • AMGIS Lifescience Ltd.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Cipla Limited
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Mylan Inc. by Viatris Inc.
  • Nephron Pharmaceuticals Corporation
  • Novartis AG
  • Perrigo Company PLC
  • Pfizer Inc.
  • Prasco Laboratories
  • Ralington Pharma LLP
  • Siemens Healthcare GmbH
  • Steris Healthcare Pvt. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Vectura Group PLC
  • Zydus Group
Product Code: MRR-C002B1C9948B

The Bronchodilators Market was valued at USD 18.37 billion in 2023, expected to reach USD 19.20 billion in 2024, and is projected to grow at a CAGR of 5.98%, to USD 27.59 billion by 2030.

Bronchodilators represent a critical segment within the broader respiratory therapeutics market, primarily used to relax and expand the air passages of the lungs, improving airflow and alleviating symptoms in conditions like asthma and COPD (Chronic Obstructive Pulmonary Disease). The necessity for bronchodilators stems from the increasing prevalence of respiratory disorders globally, particularly with the rising incidence of environmental pollution, smoking, and occupational hazards. The application of bronchodilators spans across various administration methods, including inhalers, nebulizers, and oral medications, catering to both acute and chronic therapeutic needs. These medications serve a diverse end-use scope, extending from emergency hospital care to routine home use by patients needing long-term management of their conditions. Market growth is strongly influenced by technological advancements in drug delivery systems, increased awareness, and demand for personalized medicine tailored to individual patient profiles. Additionally, rising healthcare infrastructure in developing regions presents a potential expansion opportunity. Key growth opportunities lie in the research and development of new formulations to reduce side effects and improve efficiency, as well as the exploitation of digital health platforms for better monitoring and management of respiratory conditions. However, the market is not without its challenges; stringent regulatory requirements, high development costs, and potential side effects associated with long-term use pose significant barriers. Competing treatment modalities, such as biological therapies, also threaten market share. Innovative avenues exist in the exploration of novel compounds, improvement of patient adherence technologies, and the integration of artificial intelligence for predictive healthcare delivery. The nature of the bronchodilator market is highly dynamic, marked by ongoing mergers and acquisitions aimed at product pipeline enhancement and strategic geographic expansion, necessitating continuous adaptation to regulatory landscapes and consumer demand.

KEY MARKET STATISTICS
Base Year [2023] USD 18.37 billion
Estimated Year [2024] USD 19.20 billion
Forecast Year [2030] USD 27.59 billion
CAGR (%) 5.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchodilators Market

The Bronchodilators Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of respiratory disorders worldwide
    • Growing awareness about asthma and cystic fibrosis respiratory disorders
  • Market Restraints
    • Huge expenditure required for treating chronic bronchitis
  • Market Opportunities
    • Robust research activities to develop noval bronchodilators
    • Increasing number of clinical trials to treat chronic bronchitis
  • Market Challenges
    • Side effects associated with consumption of bronchodilators

Porter's Five Forces: A Strategic Tool for Navigating the Bronchodilators Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchodilators Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchodilators Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchodilators Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchodilators Market

A detailed market share analysis in the Bronchodilators Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchodilators Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchodilators Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchodilators Market

A strategic analysis of the Bronchodilators Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchodilators Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AMGIS Lifescience Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Siemens Healthcare GmbH, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Vectura Group PLC, and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Bronchodilators Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, and Xanthine Derivative.
  • Based on Route of Administration, market is studied across Injectable, Nasal, and Oral.
  • Based on Disease, market is studied across Asthma and COPD.
  • Based on End-users, market is studied across Hospitals and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of respiratory disorders worldwide
      • 5.1.1.2. Growing awareness about asthma and cystic fibrosis respiratory disorders
    • 5.1.2. Restraints
      • 5.1.2.1. Huge expenditure required for treating chronic bronchitis
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust research activities to develop noval bronchodilators
      • 5.1.3.2. Increasing number of clinical trials to treat chronic bronchitis
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with consumption of bronchodilators
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bronchodilators Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anticholinergic Bronchodilators
  • 6.3. Beta-Adrenergic Bronchodilators
  • 6.4. Xanthine Derivative

7. Bronchodilators Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Nasal
  • 7.4. Oral

8. Bronchodilators Market, by Disease

  • 8.1. Introduction
  • 8.2. Asthma
  • 8.3. COPD

9. Bronchodilators Market, by End-users

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Specialty Clinics

10. Americas Bronchodilators Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Bronchodilators Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Bronchodilators Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AdvaCare Pharma
  • 2. AMGIS Lifescience Ltd.
  • 3. AstraZeneca PLC
  • 4. Boehringer Ingelheim International GmbH
  • 5. Cambrex Corporation
  • 6. Catalent, Inc.
  • 7. Cipla Limited
  • 8. GlaxoSmithKline PLC
  • 9. Glenmark Pharmaceuticals Limited
  • 10. Hikma Pharmaceuticals PLC
  • 11. Lupin Limited
  • 12. Mylan Inc. by Viatris Inc.
  • 13. Nephron Pharmaceuticals Corporation
  • 14. Novartis AG
  • 15. Perrigo Company PLC
  • 16. Pfizer Inc.
  • 17. Prasco Laboratories
  • 18. Ralington Pharma LLP
  • 19. Siemens Healthcare GmbH
  • 20. Steris Healthcare Pvt. Ltd.
  • 21. Sun Pharmaceutical Industries Limited
  • 22. Teva Pharmaceutical Industries Ltd.
  • 23. Thermo Fisher Scientific Inc.
  • 24. Vectura Group PLC
  • 25. Zydus Group

LIST OF FIGURES

  • FIGURE 1. BRONCHODILATORS MARKET RESEARCH PROCESS
  • FIGURE 2. BRONCHODILATORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BRONCHODILATORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BRONCHODILATORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BRONCHODILATORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BRONCHODILATORS MARKET DYNAMICS
  • TABLE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGIC BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-ADRENERGIC BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY XANTHINE DERIVATIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHODILATORS MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHODILATORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHODILATORS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHODILATORS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHODILATORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 189. BRONCHODILATORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. BRONCHODILATORS MARKET, FPNV POSITIONING MATRIX, 2023